Wanbang Pharmaceutical (301520.SZ): Information relating to promoting the core pipeline to innovate the drug huxerine A controlled-release tablets and signing cooperation agreements for new drugs such as fever is all false information

Zhitongcaijing · 2d ago

According to Zhitong Financial App News, Wanbang Pharmaceutical (301520.SZ) issued an announcement on abnormal stock trading fluctuations and risk alerts, saying that the company recently observed that the company's recent media and stock community reports that information relating to the company's promotion of the core pipeline to innovate the drug huxerine A controlled-release tablets and sign cooperation agreements for new drugs such as fever is false; the company's semi-annual results for 2026 have not been disclosed to the outside world, nor has it released a performance forecast yet.